95 related articles for article (PubMed ID: 19443568)
21. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
22. Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1).
Kalemi TG; Papazisis KT; Lambropoulos AF; Voyatzi S; Kotsis A; Kortsaris AH
Anticancer Res; 2007; 27(2):913-20. PubMed ID: 17465220
[TBL] [Abstract][Full Text] [Related]
23. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
24. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.
An WL; Cowburn RF; Li L; Braak H; Alafuzoff I; Iqbal K; Iqbal IG; Winblad B; Pei JJ
Am J Pathol; 2003 Aug; 163(2):591-607. PubMed ID: 12875979
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biological significance of GSK-3β inactivation in breast cancer-an immunohistochemical study.
Armanious H; Deschenes J; Gelebart P; Ghosh S; Mackey J; Lai R
Hum Pathol; 2010 Dec; 41(12):1657-63. PubMed ID: 20709358
[TBL] [Abstract][Full Text] [Related]
27. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.
Perkins G; Lièvre A; Ramacci C; Méatchi T; de Reynies A; Emile JF; Boige V; Tomasic G; Bachet JB; Bibeau F; Bouché O; Penault-Llorca F; Merlin JL; Laurent-Puig P
Int J Cancer; 2010 Sep; 127(6):1321-31. PubMed ID: 20049837
[TBL] [Abstract][Full Text] [Related]
28. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression.
Wong LL; Chang CF; Koay ES; Zhang D
Int J Oncol; 2009 May; 34(5):1291-301. PubMed ID: 19360341
[TBL] [Abstract][Full Text] [Related]
31. Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer.
Mongroo PS; Johnstone CN; Naruszewicz I; Leung-Hagesteijn C; Sung RK; Carnio L; Rustgi AK; Hannigan GE
Oncogene; 2004 Nov; 23(55):8959-70. PubMed ID: 15467740
[TBL] [Abstract][Full Text] [Related]
32. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
33. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
34. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
Wulfkuhle JD; Speer R; Pierobon M; Laird J; Espina V; Deng J; Mammano E; Yang SX; Swain SM; Nitti D; Esserman LJ; Belluco C; Liotta LA; Petricoin EF
J Proteome Res; 2008 Apr; 7(4):1508-17. PubMed ID: 18257519
[TBL] [Abstract][Full Text] [Related]
35. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
36. Growth factor-specific regulation of insulin receptor substrate-1 expression in MCF-7 breast carcinoma cells: effects on the insulin-like growth factor signaling pathway.
Lassarre C; Ricort JM
Endocrinology; 2003 Nov; 144(11):4811-9. PubMed ID: 12960057
[TBL] [Abstract][Full Text] [Related]
37. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
[TBL] [Abstract][Full Text] [Related]
38. Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis.
Shao GL; Wang MC; Fan XL; Zhong L; Ji SF; Sang G; Wang S
Technol Cancer Res Treat; 2018 Jan; 17():1533034617754024. PubMed ID: 29529946
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Tan AR; Yang X; Hewitt SM; Berman A; Lepper ER; Sparreboom A; Parr AL; Figg WD; Chow C; Steinberg SM; Bacharach SL; Whatley M; Carrasquillo JA; Brahim JS; Ettenberg SA; Lipkowitz S; Swain SM
J Clin Oncol; 2004 Aug; 22(15):3080-90. PubMed ID: 15284258
[TBL] [Abstract][Full Text] [Related]
40. Fas-signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells.
Shen K; Novak RF
Biochem Biophys Res Commun; 1997 Jan; 230(1):89-93. PubMed ID: 9020068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
